Bli medlem
Bli medlem

Du är här

2017-02-07

Medical Prognosis Institute: MPI - Notice to convene extraordinary general meeting

Notice to convene EXTRAORDINARY General Meeting

Indkaldelse til EKSTRAORDINÆR Generalforsamling

Der indkaldes herved til EKSTRAORDINÆR generalforsamling i Medical Prognosis
Institute A/S ("Selskabet"):
Notice is hereby given that aN EXTRAORDINARY general meeting of Medical
Prognosis Institute A/S (the "Company") will be held on:

22. februar 2017, kl. 17.30

February 22nd2017 at 5:30 pm CET

Generalforsamlingen afholdes hos:
The general meeting will be held at:

Medical Prognosis Institute A/S, Venlighedsvej 1, 2970 Hørsholm, Danmark

Dagsorden for generalforsamlingen er som følger:
The agenda for the annual general meeting is as follows:

---------------------------------------------
| 1. Valg af generalforsamlingens dirigent |
| |
| Election of Chairman of the Meeting |
---------------------------------------------

------------------------------------------------------------------------------------
| 2. Beslutning om vedtagelse af retningslinjer for incitamentsaflønning af |
| bestyrelsen og direktionen i Selskabet |
| |
| Resolution to adopt guidelines regarding the application of incentive schemes |
| to the Board of Directors and the executive management of the Company |
------------------------------------------------------------------------------------

-------------------------
| 3. Eventuelt |
| |
| Any other business |
-------------------------
Fuldstændige forslag

Complete Proposals

Re 1

Bestyrelsen foreslår, at advokat Lars Lüthjohan Jensen vælges som dirigent på
generalforsamlingen.
The Board of Directors proposes that attorney-at-law Lars Lüthjohan Jensen is
elected as chairman of the general meeting.

Re 2

Bestyrelsen foreslår at retningslinjerne vedhæftet som bilag 1 vedtages som
Selskabets retningslinjer for incitamentsaflønning af bestyrelsen og
direktionen i Selskabet i overensstemmelse med Selskabslovens § 139.
The Board of Directors proposes that the guidelines attached hereto as
schedule 1 is adopted as the Company's guidelines regarding the application
of incentive schemes to the Board of Directors and the executive management
of the Company in accordance with the Danish Companies Act section 139.

Begrundelsen for forslaget er, at Selskabets bestyrelse ved bestyrelsesmøde
den 14. juni 2016 konstaterede, at warrants udstedt af bestyrelsen til
Selskabets direktion og bestyrelse den 14. december 2014 og den 18. februar
2016 var ugyldige, idet Selskabet forinden udstedelsen skal have vedtaget og
godkendt retningslinjer på generalforsamlingen for incitamentsaflønning i
henhold til selskabslovens § 139. Formålet med vedtagelsen af vedhæftede
retningslinjer er at muliggøre generalforsamlingens udstedelse af warrants af
samme antal og på samme vilkår som de ugyldige warrants.

The reason for the proposal is that the Board of Directors on June 14th2016
resolved that warrants issued by the Board of Directors to the executive
management board and the Board of Directors of the Company on respectively
December 14th2014 and February 18th2016 were invalid as the Company prior to
such issuance duly must adopt and obtain approval of incentive guidelines
from the general meeting pursuant to the Danish Companies Act Section 139.
The purpose of the adoption of the guidelines attached is to enable the
general meeting to resolve an issue of an equal number of warrants on equal
terms to the invalid warrants.

-oo0oo-
Vedtagelseskrav:

Voting requirements for adoption:
Der gælder følgende vedtagelseskrav for forslagene, der skal være opfyldte
for, at forslagene kan anses som vedtaget:
The following voting requirements apply to the adoption of the proposals:

Forslagene under punkt 1 og 2 kan vedtages med simpelt flertal.
The proposals in item 1 and 2 require simple majority of the votes cast.

Information:

Information:
Denne indkaldelse indeholdende dagsorden og de fuldstændige forslag vil være
fremlagt på selskabets kontor til eftersyn og vil være tilgængelige på
Selskabets hjemmeside www.medical-prognosis.com fra dags dato.
This notice including agenda and the complete proposals will be available for
review the Company's premises as well as on the Company's web page
www.medical-prognosis.com from today.

Deltagelse og stemmerettigheder

Participation and voting rights

En aktionærs ret til at deltage i og stemme på den ekstraordinære
generalforsamling fastlægges på baggrund af de aktier, som aktionæren
besidder på dagen for generalforsamlingen i henhold til selskabets ejerbog.
Selskabets ejerbog føres af VP Securities A/S. Aktier skal være noteret på
navn i ejerbogen ført af VP Securities A/S eller være noteret på navn hos
Euroclear Sweden AB. Aktionærer der ejer aktier gennem en depotbank skal
koordinere med depotbanken, at aktionæren bliver noteret på navn hos
Euroclear Sweden AB forud for generalforsamlingen.
The right of a shareholder to attend and vote at the extraordinary general
meeting is determined by the shares held by the shareholder at the date of
the general meeting according to the shareholder register kept by VP
Securities A/S. The shareholder must be recorded by name in the shareholder
register kept by VP Securities A/S or by Euroclear Sweden AB. Shareholders
who hold shares through a depositary bank shall coordinate with their
depositary bank that the shareholder is duly registered by name with
Euroclear Sweden AB prior to the general meeting.

Afgivelse af fuldmagt

Aktionærer kan stemme ved fuldmagt. Som bilag til denne indkaldelse er
indeholdt en fuldmagtsblanket, som kan anvendes såfremt aktionærer ønsker at
give fuldmagt til bestyrelsen.
For the general meeting, shareholders may vote by proxy. A proxy form is
attached to this notice and may be used if the shareholder wishes to give
proxy to the Board of Directors.

Brevstemmer:

Aktionærer er berettigede til - som alternativ til at give møde og stemme på
selve generalforsamlingen - at brevstemme, dvs. afgive skriftlig stemme før
afholdelsen af generalforsamlingen. Aktionærer, der ønsker at brevstemme,
skal sende deres brevstemme til Selskabet således at denne er modtaget af
selskabet senest kl. 12.00 den 21. februar 2017. Brevstemmer kan ikke
tilbagekaldes. Vær opmærksom på at breve undertiden kan være flere dage
undervejs.
Shareholders may - instead of voting in person at the ordinary general meeting
- choose to vote by mail, i.e. voting in writing prior to the general
meeting. Any shareholder who chooses to vote by mail shall send the absentee
vote to the Company so that the has Company receives the votes at the latest
on February 21st2017 at 12:00 am. Votes delivered by mail cannot be revoked.
Please take into account that mail can be several days in transfer.

-oo0oo-
February 7th, 2017

On behalf of the Board of Directors

BILAG 1SCHEDULE 1

GENERAL GUIDELINES FOR INCENTIVE PAY FOR BOARD MEMBERS AND EXECUTIVES OF MEDICAL PROGNOSIS INSTITUTE A/SUnder the Companies Act § 139 the board of directors of a listed company
before entering a specific agreement on incentive pay with a member of the
Board of Directors or executive officers must have general guidelines for
incentive payment of board members and executive officers. The general
guidelines must be considered and approved at a General Meeting and published
on the company website.
Medical Prognosis Institute A/S has since its inception in 2004 used a
combination of fixed remuneration and variable remuneration and share-based
payments in the form of cash bonuses and warrants as a supplement. Terms of
issued warrants are described in the company's articles of association. The
Board believes that the Company is dependent on being able to attract and
retain competent directors and executive management skills at a high level.
Furthermore, the board believes that incentive remuneration of directors and
executives is essential to create further incentive for these to create value
for shareholders of the Company. Incentive Remuneration of directors and
executive officers will be designed to attract, retain and motivate such
members.
To provide incentives to achieve short-term goals the Board may agree a bonus
scheme to the Executive Board with predetermined annual milestones.
Warrant grant 2017

On June 14th2016 the board of directors resolved that 696,220 warrants in
total issued by the board of directors to the executive management board and
the board of directors of the Company on respectively December 14th2014 and
February 18th2016 were invalid as the Company had not prior to such issues
duly adopted and obtained approval from the general meeting of incentive
remuneration guidelines pursuant to the Danish Companies Act Section 139.
Consequently, in order to compensate holders of the cancelled warrants and
subject to approval from the general meeting, the company expects to grant a
number of warrants to each holder of the cancelled warrants corresponding to
the cancelled warrants. The estimated Black-Scholes value of this warrant
grant to members of the board of directors and members of the executive
management is DKK 16,013,060.

General principlesThese guidelines provide the general rules for incentive schemes for the Board
of Directors and Management Board.
The guidelines apply to incentive pay to the members of MPI's Board of
Directors and Management Board and for members of the Board of Directors and
Management Board in MPI's subsidiaries if these also have space in MPI's
board of directors.

The incentive scheme consists of Warrants. The theoretical market value of the year's total grant of Warrants - calculated on the date of grant in accordance with the International Financial Reporting Standards 2 (IFRS 2) on basis of the Black-Scholes model containing customary, market-consistent prerequisites - may not exceed DKK 5 million a year.
The allocation of the Warrants may be dependent on achieving certain goals,
but need not be. The Board's decision on the allocation of Warrants is based
on the Boards best assessment of the board member or executive and the
quality, which makes such a reward earned and with due respect to the
Company's economy.

Specifically regarding Warrants
The Board shall decide exercise price and the other terms of the Warrants
issued, except as provided by these guidelines.
Each Warrant entitles the holder to buy one share of nominally DKK 0.05 of the
Company at a fixed exercise price.
When warrants are exercised, the Company will issue new shares pursuant to the
Articles of Association in all respects to be issued with the sa...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.